Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim
Randomized, Single-blind Study to Estimate the Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  12/6/2015
Clinical Research Facility
mi
from
Aberdeen, SD
Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim
Randomized, Single-blind Study to Estimate the Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 12/6/2015
Clinical Research Facility
mi
from
Aberdeen, SD
Click here to add this to my saved trials
Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim
Randomized, Single-blind Study to Estimate the Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  12/6/2015
Clinical Research Facility
mi
from
Sioux Falls, SD
Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim
Randomized, Single-blind Study to Estimate the Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 12/6/2015
Clinical Research Facility
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim
Randomized, Single-blind Study to Estimate the Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  12/6/2015
Clinical Research Facility
mi
from
Bristol, TN
Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim
Randomized, Single-blind Study to Estimate the Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 12/6/2015
Clinical Research Facility
mi
from
Bristol, TN
Click here to add this to my saved trials
Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim
Randomized, Single-blind Study to Estimate the Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  12/6/2015
Clinical Research Facility
mi
from
El Paso, TX
Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim
Randomized, Single-blind Study to Estimate the Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 12/6/2015
Clinical Research Facility
mi
from
El Paso, TX
Click here to add this to my saved trials
Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim
Randomized, Single-blind Study to Estimate the Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  12/6/2015
Clinical Research Facility
mi
from
Danville, VA
Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim
Randomized, Single-blind Study to Estimate the Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 12/6/2015
Clinical Research Facility
mi
from
Danville, VA
Click here to add this to my saved trials
Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim
Randomized, Single-blind Study to Estimate the Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  12/6/2015
Clinical Research Facility
mi
from
Burien, WA
Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim
Randomized, Single-blind Study to Estimate the Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 12/6/2015
Clinical Research Facility
mi
from
Burien, WA
Click here to add this to my saved trials
Epigenetics and Psychoneurologic Symptoms in Women With Breast Cancer
Epigenetic Factors Associated With Symptoms and Complications of Chronic Disorders
Status: Enrolling
Updated:  12/7/2015
Peninsula Cancer Institute
mi
from
Newport News, VA
Epigenetics and Psychoneurologic Symptoms in Women With Breast Cancer
Epigenetic Factors Associated With Symptoms and Complications of Chronic Disorders
Status: Enrolling
Updated: 12/7/2015
Peninsula Cancer Institute
mi
from
Newport News, VA
Click here to add this to my saved trials
Epigenetics and Psychoneurologic Symptoms in Women With Breast Cancer
Epigenetic Factors Associated With Symptoms and Complications of Chronic Disorders
Status: Enrolling
Updated:  12/7/2015
Virginia Commonwealth University
mi
from
Richmond, VA
Epigenetics and Psychoneurologic Symptoms in Women With Breast Cancer
Epigenetic Factors Associated With Symptoms and Complications of Chronic Disorders
Status: Enrolling
Updated: 12/7/2015
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
Whole Body Magnetic Resonance Imaging (MRI) for Detection of Cancer Metastases
Whole Body MRI for Detection of Cancer Metastases
Status: Enrolling
Updated:  12/7/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Whole Body Magnetic Resonance Imaging (MRI) for Detection of Cancer Metastases
Whole Body MRI for Detection of Cancer Metastases
Status: Enrolling
Updated: 12/7/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Self-Care for Lymphedema in Patients With Breast Cancer
Breast Cancer Treatment Related Lymphedema Self Care Practices
Status: Enrolling
Updated:  12/7/2015
Vanderbilt-Ingram Cancer Center - Cool Springs
mi
from
Nashville, TN
Self-Care for Lymphedema in Patients With Breast Cancer
Breast Cancer Treatment Related Lymphedema Self Care Practices
Status: Enrolling
Updated: 12/7/2015
Vanderbilt-Ingram Cancer Center - Cool Springs
mi
from
Nashville, TN
Click here to add this to my saved trials
Self-Care for Lymphedema in Patients With Breast Cancer
Breast Cancer Treatment Related Lymphedema Self Care Practices
Status: Enrolling
Updated:  12/7/2015
Vanderbilt-Ingram Cancer Center at Franklin
mi
from
Nashville, TN
Self-Care for Lymphedema in Patients With Breast Cancer
Breast Cancer Treatment Related Lymphedema Self Care Practices
Status: Enrolling
Updated: 12/7/2015
Vanderbilt-Ingram Cancer Center at Franklin
mi
from
Nashville, TN
Click here to add this to my saved trials
Self-Care for Lymphedema in Patients With Breast Cancer
Breast Cancer Treatment Related Lymphedema Self Care Practices
Status: Enrolling
Updated:  12/7/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Self-Care for Lymphedema in Patients With Breast Cancer
Breast Cancer Treatment Related Lymphedema Self Care Practices
Status: Enrolling
Updated: 12/7/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Assessment of Progesterone Receptors in Breast Carcinoma by Positron Emission Tomography (PET) Using Fluoro Furanyl Norprogesterone (FFNP)
Labeling of Receptor Ligands and Other Compounds With Halogen Radionuclides: Assessment of Progesterone Receptors in Breast Carcinoma by Positron Emission Tomography (PET) Using FFNP
Status: Enrolling
Updated:  12/7/2015
Washington University/ Barnes-Jewish Hospital
mi
from
Saint Louis, MO
Assessment of Progesterone Receptors in Breast Carcinoma by Positron Emission Tomography (PET) Using Fluoro Furanyl Norprogesterone (FFNP)
Labeling of Receptor Ligands and Other Compounds With Halogen Radionuclides: Assessment of Progesterone Receptors in Breast Carcinoma by Positron Emission Tomography (PET) Using FFNP
Status: Enrolling
Updated: 12/7/2015
Washington University/ Barnes-Jewish Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Doxorubicin, Cyclophosphamide, and/or Paclitaxel in Treating Women With Nonmetastatic Breast Cancer
A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)/Cyclophosphamide ©) and/or Weekly Paclitaxel
Status: Enrolling
Updated:  12/8/2015
Duke Cancer Institute
mi
from
Durham, NC
Doxorubicin, Cyclophosphamide, and/or Paclitaxel in Treating Women With Nonmetastatic Breast Cancer
A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)/Cyclophosphamide ©) and/or Weekly Paclitaxel
Status: Enrolling
Updated: 12/8/2015
Duke Cancer Institute
mi
from
Durham, NC
Click here to add this to my saved trials
Reach for Health Study: Obesity-related Mechanisms and Mortality in Breast Cancer Survivors
Obesity-related Mechanisms and Mortality in Breast Cancer Survivors
Status: Enrolling
Updated:  12/8/2015
Moores UCSD Cancer Center
mi
from
La Jolla, CA
Reach for Health Study: Obesity-related Mechanisms and Mortality in Breast Cancer Survivors
Obesity-related Mechanisms and Mortality in Breast Cancer Survivors
Status: Enrolling
Updated: 12/8/2015
Moores UCSD Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors
A Pilot Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors (I-CREST)
Status: Enrolling
Updated:  12/8/2015
Western Regional Medical Center, Inc
mi
from
Goodyear, AZ
Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors
A Pilot Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors (I-CREST)
Status: Enrolling
Updated: 12/8/2015
Western Regional Medical Center, Inc
mi
from
Goodyear, AZ
Click here to add this to my saved trials
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated:  12/8/2015
Helen F. Graham Cancer Center
mi
from
Newark, DE
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated: 12/8/2015
Helen F. Graham Cancer Center
mi
from
Newark, DE
Click here to add this to my saved trials
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated:  12/8/2015
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated: 12/8/2015
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Click here to add this to my saved trials
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated:  12/8/2015
Elkhart Clinic, LLC
mi
from
Elkhart, IN
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated: 12/8/2015
Elkhart Clinic, LLC
mi
from
Elkhart, IN
Click here to add this to my saved trials
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated:  12/8/2015
Oncology Hematology Associates of SW Indiana
mi
from
Evansville, IN
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated: 12/8/2015
Oncology Hematology Associates of SW Indiana
mi
from
Evansville, IN
Click here to add this to my saved trials
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated:  12/8/2015
Indiana University Cancer Center
mi
from
Indianapolis, IN
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated: 12/8/2015
Indiana University Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated:  12/8/2015
Quality Cancer Center (MCGOP)
mi
from
Indianapolis, IN
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated: 12/8/2015
Quality Cancer Center (MCGOP)
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated:  12/8/2015
Community Regional Cancer Center
mi
from
Indianapolis, IN
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated: 12/8/2015
Community Regional Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated:  12/8/2015
Medical Consultants, P.C.
mi
from
Muncie, IN
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated: 12/8/2015
Medical Consultants, P.C.
mi
from
Muncie, IN
Click here to add this to my saved trials
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated:  12/8/2015
Center for Cancer Care, Inc., P.C.
mi
from
New Albany, IN
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated: 12/8/2015
Center for Cancer Care, Inc., P.C.
mi
from
New Albany, IN
Click here to add this to my saved trials
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated:  12/8/2015
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated: 12/8/2015
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated:  12/8/2015
AP&S Clinic
mi
from
Terre Haute, IN
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated: 12/8/2015
AP&S Clinic
mi
from
Terre Haute, IN
Click here to add this to my saved trials
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80
Status: Enrolling
Updated:  12/8/2015
Elkhart Clinic, LLC
mi
from
Elkhart, IN
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80
Status: Enrolling
Updated: 12/8/2015
Elkhart Clinic, LLC
mi
from
Elkhart, IN
Click here to add this to my saved trials
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80
Status: Enrolling
Updated:  12/8/2015
Fort Wayne Oncology & Hematology, Inc
mi
from
Fort Wayne, IN
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80
Status: Enrolling
Updated: 12/8/2015
Fort Wayne Oncology & Hematology, Inc
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80
Status: Enrolling
Updated:  12/8/2015
Center for Cancer Care at Goshen Health System
mi
from
Goshen, IN
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80
Status: Enrolling
Updated: 12/8/2015
Center for Cancer Care at Goshen Health System
mi
from
Goshen, IN
Click here to add this to my saved trials
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80
Status: Enrolling
Updated:  12/8/2015
Indiana University Cancer Center
mi
from
Indianapolis, IN
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80
Status: Enrolling
Updated: 12/8/2015
Indiana University Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80
Status: Enrolling
Updated:  12/8/2015
Arnett Cancer Care
mi
from
Lafayette, IN
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80
Status: Enrolling
Updated: 12/8/2015
Arnett Cancer Care
mi
from
Lafayette, IN
Click here to add this to my saved trials
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80
Status: Enrolling
Updated:  12/8/2015
Medical Consultants, P.C.
mi
from
Muncie, IN
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80
Status: Enrolling
Updated: 12/8/2015
Medical Consultants, P.C.
mi
from
Muncie, IN
Click here to add this to my saved trials
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80
Status: Enrolling
Updated:  12/8/2015
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80
Status: Enrolling
Updated: 12/8/2015
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80
Status: Enrolling
Updated:  12/8/2015
AP&S Clinic
mi
from
Terre Haute, IN
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80
Status: Enrolling
Updated: 12/8/2015
AP&S Clinic
mi
from
Terre Haute, IN
Click here to add this to my saved trials
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study: Hoosier Oncology Group COE-01
Status: Enrolling
Updated:  12/8/2015
Cancer Care Center of Southern Indiana
mi
from
Bloomington, IN
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study: Hoosier Oncology Group COE-01
Status: Enrolling
Updated: 12/8/2015
Cancer Care Center of Southern Indiana
mi
from
Bloomington, IN
Click here to add this to my saved trials
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study: Hoosier Oncology Group COE-01
Status: Enrolling
Updated:  12/8/2015
Fort Wayne Oncology & Hematology, Inc
mi
from
Fort Wayne, IN
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study: Hoosier Oncology Group COE-01
Status: Enrolling
Updated: 12/8/2015
Fort Wayne Oncology & Hematology, Inc
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study: Hoosier Oncology Group COE-01
Status: Enrolling
Updated:  12/8/2015
Center for Cancer Care at Goshen Health System
mi
from
Goshen, IN
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study: Hoosier Oncology Group COE-01
Status: Enrolling
Updated: 12/8/2015
Center for Cancer Care at Goshen Health System
mi
from
Goshen, IN
Click here to add this to my saved trials
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study: Hoosier Oncology Group COE-01
Status: Enrolling
Updated:  12/8/2015
Indiana University Cancer Center
mi
from
Indianapolis, IN
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study: Hoosier Oncology Group COE-01
Status: Enrolling
Updated: 12/8/2015
Indiana University Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study: Hoosier Oncology Group COE-01
Status: Enrolling
Updated:  12/8/2015
Mary Lou Mayer, M.D.
mi
from
Indianapolis, IN
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study: Hoosier Oncology Group COE-01
Status: Enrolling
Updated: 12/8/2015
Mary Lou Mayer, M.D.
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study: Hoosier Oncology Group COE-01
Status: Enrolling
Updated:  12/8/2015
Community Regional Cancer Center
mi
from
Indianapolis, IN
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study: Hoosier Oncology Group COE-01
Status: Enrolling
Updated: 12/8/2015
Community Regional Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study: Hoosier Oncology Group COE-01
Status: Enrolling
Updated:  12/8/2015
Arnett Cancer Care
mi
from
Lafayette, IN
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study: Hoosier Oncology Group COE-01
Status: Enrolling
Updated: 12/8/2015
Arnett Cancer Care
mi
from
Lafayette, IN
Click here to add this to my saved trials
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study: Hoosier Oncology Group COE-01
Status: Enrolling
Updated:  12/8/2015
Horizon Oncology Center
mi
from
Lafayette, IN
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study: Hoosier Oncology Group COE-01
Status: Enrolling
Updated: 12/8/2015
Horizon Oncology Center
mi
from
Lafayette, IN
Click here to add this to my saved trials
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study: Hoosier Oncology Group COE-01
Status: Enrolling
Updated:  12/8/2015
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study: Hoosier Oncology Group COE-01
Status: Enrolling
Updated: 12/8/2015
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study: Hoosier Oncology Group COE-01
Status: Enrolling
Updated:  12/8/2015
Baylor College of Medicine - Methodist Breast Center
mi
from
Houston, TX
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study: Hoosier Oncology Group COE-01
Status: Enrolling
Updated: 12/8/2015
Baylor College of Medicine - Methodist Breast Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study: Hoosier Oncology Group COE-01
Status: Enrolling
Updated:  12/8/2015
Instituto de Enfermedades Neoplasticas (INEN)
mi
from
Lima,
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study: Hoosier Oncology Group COE-01
Status: Enrolling
Updated: 12/8/2015
Instituto de Enfermedades Neoplasticas (INEN)
mi
from
Lima,
Click here to add this to my saved trials
Cathepsin Activatable Fluorescent Probe
A Phase I Study of the Safety and Activation of a Cathepsin-Activatable Fluorescent Cancer Specific Probe LUM015
Status: Enrolling
Updated:  12/8/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Cathepsin Activatable Fluorescent Probe
A Phase I Study of the Safety and Activation of a Cathepsin-Activatable Fluorescent Cancer Specific Probe LUM015
Status: Enrolling
Updated: 12/8/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Pilot Mammography Reader Study to Assess Breast Cancer Detection in FFDM Plus DBT Versus FFDM Alone
A Multi-Reader Multi-Case Controlled Clinical Trial to Evaluate the Comparative Accuracy of the Fujifilm Full Field Digital Mammography (FFDM) Plus Digital Breast Tomosynthesis (DBT) Versus FFDM Alone in the Detection of Breast Cancer
Status: Enrolling
Updated:  12/8/2015
Scottsdale Medical Imaging, Limited (SMIL)
mi
from
Scottsdale, AZ
Pilot Mammography Reader Study to Assess Breast Cancer Detection in FFDM Plus DBT Versus FFDM Alone
A Multi-Reader Multi-Case Controlled Clinical Trial to Evaluate the Comparative Accuracy of the Fujifilm Full Field Digital Mammography (FFDM) Plus Digital Breast Tomosynthesis (DBT) Versus FFDM Alone in the Detection of Breast Cancer
Status: Enrolling
Updated: 12/8/2015
Scottsdale Medical Imaging, Limited (SMIL)
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Pilot Mammography Reader Study to Assess Breast Cancer Detection in FFDM Plus DBT Versus FFDM Alone
A Multi-Reader Multi-Case Controlled Clinical Trial to Evaluate the Comparative Accuracy of the Fujifilm Full Field Digital Mammography (FFDM) Plus Digital Breast Tomosynthesis (DBT) Versus FFDM Alone in the Detection of Breast Cancer
Status: Enrolling
Updated:  12/8/2015
Elizabeth Wende Breast Care, LLC (EWBC)
mi
from
Rochester, NY
Pilot Mammography Reader Study to Assess Breast Cancer Detection in FFDM Plus DBT Versus FFDM Alone
A Multi-Reader Multi-Case Controlled Clinical Trial to Evaluate the Comparative Accuracy of the Fujifilm Full Field Digital Mammography (FFDM) Plus Digital Breast Tomosynthesis (DBT) Versus FFDM Alone in the Detection of Breast Cancer
Status: Enrolling
Updated: 12/8/2015
Elizabeth Wende Breast Care, LLC (EWBC)
mi
from
Rochester, NY
Click here to add this to my saved trials
Pilot Mammography Reader Study to Assess Breast Cancer Detection in FFDM Plus DBT Versus FFDM Alone
A Multi-Reader Multi-Case Controlled Clinical Trial to Evaluate the Comparative Accuracy of the Fujifilm Full Field Digital Mammography (FFDM) Plus Digital Breast Tomosynthesis (DBT) Versus FFDM Alone in the Detection of Breast Cancer
Status: Enrolling
Updated:  12/8/2015
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Pilot Mammography Reader Study to Assess Breast Cancer Detection in FFDM Plus DBT Versus FFDM Alone
A Multi-Reader Multi-Case Controlled Clinical Trial to Evaluate the Comparative Accuracy of the Fujifilm Full Field Digital Mammography (FFDM) Plus Digital Breast Tomosynthesis (DBT) Versus FFDM Alone in the Detection of Breast Cancer
Status: Enrolling
Updated: 12/8/2015
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials